4.4 Article

Diverse Mechanisms of AKT Pathway Activation in Human Malignancy

Journal

CURRENT CANCER DRUG TARGETS
Volume 13, Issue 3, Pages 234-244

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009611313030002

Keywords

AKT/PKB kinases; hemimegalencephaly; human malignancy; hypoglycemia; oncogenes; proteus syndrome; targeted therapies; tumor suppressor genes

Categories

Funding

  1. National Cancer Institute [CA77429, CA06927]

Ask authors/readers for more resources

AKT/PKB (Protein Kinase B) are central proteins mediating signals from receptor tyrosine kinases and phosphatidylinositol 3-kinase. AKT kinases are involved in a number of important cellular processes including cell proliferation and survival, cell size in response to nutrient availability, tumor invasion/metastasis, and angiogenesis. Various components of the AKT signaling pathway are encoded by tumor suppressor genes and oncogenes whose loss or activation, respectively, plays an important role in tumorigenesis. The growing body of evidence connecting deregulated AKT signaling with sporadic human cancers and inherited cancer predisposition syndromes is discussed. We also highlight new findings regarding the involvement of activating mutations of AKT1, AKT2, and AKT3 in somatic overgrowth disorders: Proteus syndrome, hypoglycemia with hypertrophy, and hemimegalencephaly, respectively. In addition, we review recent literature documenting the various ways the AKT signaling pathway is activated in human cancers and consequences for molecularly targeted therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available